Biotech and Medtech Stocks Surge in After-Hours Trading for Major Companies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 15 2025
0mins
Should l Buy PEN?
Source: NASDAQ.COM
Surge in Healthcare Stocks: On September 12, several healthcare and biotech stocks, including Penumbra, Check-Cap, Adaptimmune Therapeutics, and NewAmsterdam Pharma, saw significant after-hours trading gains, driven by strategic announcements and clinical milestones, despite some movements occurring without direct news.
Penumbra's Stock Performance: Penumbra Inc. experienced a rebound in after-hours trading, rising 6.28% to $289.86, following a decline during regular hours. The company raised its full-year revenue guidance and appointed a new president, indicating confidence in its growth trajectory.
Check-Cap's Merger Announcement: Check-Cap Ltd. saw its stock soar by 191.22% after announcing a merger with MBody AI, which aims to enhance its colorectal cancer screening technology with AI capabilities, potentially transforming its strategic direction.
NewAmsterdam Pharma's Regulatory Progress: NewAmsterdam Pharma's shares rose 8.23% after-hours, driven by positive investor sentiment regarding its lead candidate obicetrapib and recent regulatory milestones, including accepted Marketing Authorization Applications by the EMA and promising trial data related to Alzheimer's disease biomarkers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 336.740
Low
266.00
Averages
344.64
High
388.00
Current: 336.740
Low
266.00
Averages
344.64
High
388.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Potential Violation Investigation: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE: PEN) regarding its sale to Boston Scientific Corporation, which involves either $374 in cash or 3.8721 shares of Boston Scientific common stock, potentially indicating breaches of fiduciary duties to shareholders.
- Merger Transaction Impact: Upon completion of the merger between Brink’s Company (NYSE: BCO) and NCR Atleos Corporation, Brink’s shareholders will own approximately 78% of the combined entity, which could significantly affect shareholder rights and future earnings.
- Cash Acquisition Proposal: AES Corporation (NYSE: AES) is being acquired by a consortium led by Global Infrastructure Partners and EQT Infrastructure VI fund for $15.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Legal Rights Consultation: Halper Sadeh LLC encourages shareholders to consult about their rights and options at no cost, emphasizing their capability in providing legal support against securities fraud and corporate misconduct.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Thermon Group Holdings and CECO Environmental, where Thermon shareholders may choose to receive $10 in cash and 0.6840 shares of CECO stock per share, or $63.89 in cash, or 0.8110 shares of CECO stock, which will directly impact shareholder financial returns.
- Penumbra Transaction Details: In the deal involving Penumbra, Inc. and Boston Scientific Corporation, Penumbra shareholders are expected to receive either 3.8721 shares of Boston Scientific common stock or $374 in cash per share, providing significant cash flow and potential stock appreciation for shareholders.
- Brink's Merger Proposal: In the merger between Brink’s Company and NCR Atleos Corporation, NCR Atleos shareholders are expected to receive $30 in cash and 0.1574 shares of Brink’s common stock per share, offering NCR shareholders stable cash returns and future equity appreciation opportunities.
- Allegiant Merger Outlook: The merger between Allegiant Travel Company and Sun Country Airlines is expected to result in Allegiant shareholders owning approximately 67% of the combined company, significantly enhancing Allegiant's competitiveness and market share in the airline industry.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Potential Violation Investigation: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE:PEN) regarding its sale to Boston Scientific Corporation for either $374 in cash or 3.8721 shares of Boston Scientific common stock, raising concerns about shareholder rights.
- Shareholder Rights Protection: SunOpta Inc. (NASDAQ:STKL) is being sold to Refresco for $6.50 per share in cash, prompting Halper Sadeh LLC to remind shareholders to be aware of their rights and options to ensure transparency and fairness in the transaction.
- Merger Transaction Review: The merger between Brink's Company (NYSE:BCO) and NCR Atleos Corporation will result in Brink's shareholders owning approximately 78% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation for shareholders.
- Legal Support Services: LINKBANCORP, Inc. (NASDAQ:LNKB) is selling for 0.1350 shares of Burke & Herbert common stock per share, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their rights and possible legal remedies.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Acquisition Investigations: Monteverde & Associates is investigating the transaction between Penumbra, Inc. and Boston Scientific Corporation, where shareholders are expected to receive either 3.8721 shares of Boston Scientific or $374 in cash per share, potentially impacting shareholder returns significantly.
- SunOpta Acquisition Details: In the deal with Pegasus BidCo B.V., SunOpta Inc. shareholders are expected to receive $6.50 per share in cash, providing a direct cash return that enhances the investment value for shareholders.
- LINKBANCORP Transaction Structure: LINKBANCORP, Inc. shareholders will receive 0.1350 shares of Burke & Herbert common stock in their transaction, which is expected to affect the shareholder structure and future earnings potential.
- Merger Disclosure: Vine Hill Capital Investment Corp. shareholders will receive shares of the newly combined company in its merger with CoinShares International Limited, which may present new growth opportunities for shareholders.
See More
Penumbra Reports Significant Q4 Profit Growth
- Profit Growth: Penumbra Inc. reported a fourth-quarter profit of $47.34 million, translating to $1.20 per share, which marks a significant increase from last year's $33.68 million and $0.86 per share, indicating enhanced profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $46.51 million or $1.18 per share, reflecting ongoing growth and stability in its core business operations.
- Revenue Increase: The company's revenue rose by 22.1% to $385.38 million compared to $315.51 million last year, showcasing strong market demand and sales performance.
- Market Positioning: With substantial improvements in both profit and revenue, Penumbra strengthens its competitive position in the medical device industry, likely attracting increased investor interest in its future growth potential.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Potential Violation Investigation: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE: PEN) regarding its sale to Boston Scientific Corporation, which involves either $374 in cash or 3.8721 shares of Boston Scientific common stock, potentially indicating breaches of fiduciary duties to shareholders.
- Merger Transaction Impact: Upon completion of the merger between Brink’s Company (NYSE: BCO) and NCR Atleos Corporation, Brink’s shareholders will own approximately 78% of the combined entity, which could significantly affect shareholder rights and future earnings.
- Cash Acquisition Proposal: AES Corporation (NYSE: AES) is being acquired by a consortium led by Global Infrastructure Partners and EQT Infrastructure VI fund for $15.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Legal Rights Consultation: Halper Sadeh LLC encourages shareholders to consult about their rights and options at no cost, emphasizing their capability in providing legal support against securities fraud and corporate misconduct.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Thermon Group Holdings and CECO Environmental, where Thermon shareholders may choose to receive $10 in cash and 0.6840 shares of CECO stock per share, or $63.89 in cash, or 0.8110 shares of CECO stock, which will directly impact shareholder financial returns.
- Penumbra Transaction Details: In the deal involving Penumbra, Inc. and Boston Scientific Corporation, Penumbra shareholders are expected to receive either 3.8721 shares of Boston Scientific common stock or $374 in cash per share, providing significant cash flow and potential stock appreciation for shareholders.
- Brink's Merger Proposal: In the merger between Brink’s Company and NCR Atleos Corporation, NCR Atleos shareholders are expected to receive $30 in cash and 0.1574 shares of Brink’s common stock per share, offering NCR shareholders stable cash returns and future equity appreciation opportunities.
- Allegiant Merger Outlook: The merger between Allegiant Travel Company and Sun Country Airlines is expected to result in Allegiant shareholders owning approximately 67% of the combined company, significantly enhancing Allegiant's competitiveness and market share in the airline industry.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Potential Violation Investigation: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE:PEN) regarding its sale to Boston Scientific Corporation for either $374 in cash or 3.8721 shares of Boston Scientific common stock, raising concerns about shareholder rights.
- Shareholder Rights Protection: SunOpta Inc. (NASDAQ:STKL) is being sold to Refresco for $6.50 per share in cash, prompting Halper Sadeh LLC to remind shareholders to be aware of their rights and options to ensure transparency and fairness in the transaction.
- Merger Transaction Review: The merger between Brink's Company (NYSE:BCO) and NCR Atleos Corporation will result in Brink's shareholders owning approximately 78% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation for shareholders.
- Legal Support Services: LINKBANCORP, Inc. (NASDAQ:LNKB) is selling for 0.1350 shares of Burke & Herbert common stock per share, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their rights and possible legal remedies.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Acquisition Investigations: Monteverde & Associates is investigating the transaction between Penumbra, Inc. and Boston Scientific Corporation, where shareholders are expected to receive either 3.8721 shares of Boston Scientific or $374 in cash per share, potentially impacting shareholder returns significantly.
- SunOpta Acquisition Details: In the deal with Pegasus BidCo B.V., SunOpta Inc. shareholders are expected to receive $6.50 per share in cash, providing a direct cash return that enhances the investment value for shareholders.
- LINKBANCORP Transaction Structure: LINKBANCORP, Inc. shareholders will receive 0.1350 shares of Burke & Herbert common stock in their transaction, which is expected to affect the shareholder structure and future earnings potential.
- Merger Disclosure: Vine Hill Capital Investment Corp. shareholders will receive shares of the newly combined company in its merger with CoinShares International Limited, which may present new growth opportunities for shareholders.
See More
Penumbra Reports Significant Q4 Profit Growth
- Profit Growth: Penumbra Inc. reported a fourth-quarter profit of $47.34 million, translating to $1.20 per share, which marks a significant increase from last year's $33.68 million and $0.86 per share, indicating enhanced profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $46.51 million or $1.18 per share, reflecting ongoing growth and stability in its core business operations.
- Revenue Increase: The company's revenue rose by 22.1% to $385.38 million compared to $315.51 million last year, showcasing strong market demand and sales performance.
- Market Positioning: With substantial improvements in both profit and revenue, Penumbra strengthens its competitive position in the medical device industry, likely attracting increased investor interest in its future growth potential.
See More
